A study to assess if a gel made from nutmeg (Myristica fragrans) can improve gum health in smokers who have moderate gum disease (Stage II periodontitis)

Evaluation of efficacy of 0.3% Nutmeg (Myristica fragrans) Gel as Local Drug Delivery in smokers with Stage-II Periodontitis – A Randomised clinical study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096054

Enrollment

Registered

2025-10-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: 0.3% Nutmeg (Myristica fragrans) Gel: Along with SRP, 1 ml of 0.3% nutmeg gel will be injected into the periodontal pocket with the help of a syringe immediately after SRP and coe pack

Eligibility

Inclusion criteria

Inclusion criteria: Have a probing pocket depth (PPD) of less than or equal to 5 mm Having clinical attachment loss (CAL) between 3 to 4 mm No history of periodontal therapy in the preceding 6 months No use of antibiotics in the preceding 6 months

Exclusion criteria

Exclusion criteria: Subjects with allergies Tobacco users in any form other than smoking Medically compromised individuals

Design outcomes

Primary

Measure	Time frame
To evaluate the therapeutic efficacy of 0.3% Nutmeg (Myristica fragrans) gel when used as a local drug delivery (LDD) in smokers diagnosed with Stage-II periodontitisTimepoint: at 3 months after placing LDD	—

Secondary

Measure	Time frame
To assess the reduction in probing pocket depth (PPD) & Clinical Attachment Level (CAL) following application of nutmeg gel.Timepoint: at 3 months	—

Countries

India

Contacts

Public ContactGracelin Solomon J

SRM UNIVERSITY

ravishak@srmist.edu.in09848113248

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026